Author:
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1
White NJ, 1998. Preventing antimalarial drug resistance through combinations. Drug Resist Updates 1 :3–9.
-
2
White NJ, Nosten F, Looareesuwan S, Watkins WM, Marsh K, Snow RW, Kokwara G, Ouma J, Hien TT, Molyneux ME, Taylor TE, Newbold CI, Ruebush TK II, Danis M, Greenwood BM, Anderson RM, Olliaro P, 1999. Averting a malaria disaster. Lancet 353 :1965–1967.
-
3
WHO, 1998. The Use of Artemisinin and Its Derivatives as Anti-Malarial Drugs: Report of a Joint CTD/DMP/TDR Informal Consultation. Geneva: World Health Organization. WHO Document WHO/MAL/98.1086
-
4
Nosten F, van Vugt M, Price R, Luxemburger C, Thway KL, Brockman A, McGready R, ter Kuile F, Looareesuwan S, White NJ, 2000. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet 356 :297–302.
-
5
White NJ, 1997. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother 41 :1413–1422.
-
6
Price RN, Nosten F, Luxemburger C, ter Kuile FO, Paiphun L, Chongsuphajaisiddhi T, White NJ, 1996. Effects of artemisinin derivatives on malaria transmissibility. Lancet 347 :1654–1658.
-
7
Doherty F, Sadiq AD, Bayo L, Alloueche A, Olliaro P, Milligan P, von Seidlein L, Pinder M, 1999. A randomized safety and tolerability trial of artresunate plus sulfadoxine-pyrimethamine versus sulfadoxine-pyrimethamine alone for the treatment of uncomplicated malaria in Gambian children. Trans R Soc Trop Med Hyg 93 :543–546.
-
8
von Seidlein L, Jawara M, Coleman R, Doherty T, Walraven G, Targett G, 2001. Parasitaemia and gametocytaemia after treatment with chloroquine, pyrimethamine/sulfadoxine, and pyrimethamine/sulfadoxine combined with artesunate in young Gambians with uncomplicated malaria. Trop Med Int Health 6 :92–98.
-
9
von Seidlein L, Milligan P, Pinder M, Bojang K, Anyalebechi C, Gosling R, Coleman R, Ude JI, Sadiq A, Duraisingh M, Warhurst D, Alloueche A, Targett A, McAdam K, Greenwood B, Walraven G, Olliaro P, Doherty T, 2000. Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in Gambian children: a double-blind, randomised, controlled trial. Lancet 355 :352–357.
-
10
Marquiño W, MacArthur JR, Barat LM, Oblitas FE, Arrunátegui M, Garavito G, Chafloque ML, Pardavé B, Gutierrez S, Arróspide N, Carrillo C, Cabezas C, Ruebush TK II, 2003. Efficacy of chloroquine, sulfadoxine-pyrimethamine, and mefloquine for the treatment of uncomplicated Plasmodium falciparum malaria on the north coast of Peru. Am J Trop Med Hyg 68 :120–123.
-
11
Ministerio de Salud, Peru, 1999. Política Nacional de Medicamentos para el Control de la Malaria en el Perú. Lima: MINSA.
-
12
Bruce-Chwatt LJ, Black RH, Canfield CJ, Clyde DR, Peters W, 1986. Chemotherapy of Malaria. World Health Organization Monograph Series No. 27, Geneva: World Health Organization.
-
13
Pan American Health Organization, 1998. Evaluation of the Therapeutic Efficacy of Drugs for the Treatment of Uncomplicated Plasmodium falciparum Malaria in the Americas. Washington, DC: Pan American Health Organization. OPS/HCP/HCT/113/98.
-
14
Ministry of Public Health, Thailand, 1996. Post-Registration Surveillance of the Artemisinin Derivatives Used Operationally in Thailand. Nonthaburi, Thailand: Technical Division, Food and Drug Administration.
-
15
Ribiero IR, Olliaro P, 1998. Safety of artemisinin and its derivatives: a review of published and unpublished clinical trials. Med Trop (Mars) 58 :50–53.
-
16
Botero D, Restrepo M, Montoya A, 1985. Prospective double-blind trial of two different doses of mefloquine plus pyrimethamine-sulfadoxine compared with pyrimethamine-sulfadoxine alone in the treatment of falciparum malaria. Bull World Health Organ 3 :731–737.
-
17
Reyes S, Osanai CH, Costa Passos AD, 1986. Resistência in vivo do Plasmodium falciparum as 4-aminoquinoleínas e á associação sulfadoxina-pirimetamina. II. Estudio de Manaus, Amazonas 1983–1984. Rev Bras Mal Doencas Trop 38 :37–44.
-
18
Osorio LE, Giraldo LE, Grajales LF, Arriaga AL, Andrade AL, Ruebush TK, Barat LM, 1999. Assessment of the therapeutic response of Plasmodium falciparum to chloroquine and sulfadoxine-pyrimethamine in an area of low malaria transmission in Colombia. Am J Trop Med Hyg 61 :968–972.
-
19
Nwanyanwu OC, Ziba C, Macheso A, Kazembe P, 2000. Efficacy of sulphadoxine-pyrimethamine for acute uncomplicated malaria due to Plasmodium falciparum in Malawian children under five years old. Trop Med Int Health 5 :355–358.
-
20
White NJ, 1992. Antimalarial drug resistance: the pace quickens. J Antimicrob Agents Chemother 30 :571–585.
-
21
Watkins WM, Mosobo M, 1993. Treatment of Plasmodium falciparum malaria with PSD: selective pressure for resistance is a function of long elimination half life. Trans R Soc Trop Med Hyg 87 :75–78.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 59 | 59 | 8 |
| Full Text Views | 239 | 73 | 0 |
| PDF Downloads | 44 | 14 | 0 |
EFFICACY AND TOLERABILITY OF ARTESUNATE PLUS SULFADOXINE-PYRIMETHAMINE AND SULFADOXINE-PYRIMETHAMINE ALONE FOR THE TREATMENT OF UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA IN PERU
WILMER MARQUIÑO
WILMER MARQUIÑO
Instituto Nacional de Salud, Lima, Peru; Dirección Sub-Regional de Salud Piura II, Ministerio de Salud, Sullana, Peru; Office of the Director, National Center for Infectious Diseases, Centers for Disease Control and Prevention, U.S. Naval Medical Research Center Detachment, Lima, Peru
Search for other papers by WILMER MARQUIÑO in
Current site
Google Scholar
PubMed
Search for other papers by WILMER MARQUIÑO in
Current site
Google Scholar
PubMed
LAURA YLQUIMICHE
LAURA YLQUIMICHE
Instituto Nacional de Salud, Lima, Peru; Dirección Sub-Regional de Salud Piura II, Ministerio de Salud, Sullana, Peru; Office of the Director, National Center for Infectious Diseases, Centers for Disease Control and Prevention, U.S. Naval Medical Research Center Detachment, Lima, Peru
Search for other papers by LAURA YLQUIMICHE in
Current site
Google Scholar
PubMed
Search for other papers by LAURA YLQUIMICHE in
Current site
Google Scholar
PubMed
YGOR HERMENEGILDO
YGOR HERMENEGILDO
Instituto Nacional de Salud, Lima, Peru; Dirección Sub-Regional de Salud Piura II, Ministerio de Salud, Sullana, Peru; Office of the Director, National Center for Infectious Diseases, Centers for Disease Control and Prevention, U.S. Naval Medical Research Center Detachment, Lima, Peru
Search for other papers by YGOR HERMENEGILDO in
Current site
Google Scholar
PubMed
Search for other papers by YGOR HERMENEGILDO in
Current site
Google Scholar
PubMed
ANA MARIA PALACIOS
ANA MARIA PALACIOS
Instituto Nacional de Salud, Lima, Peru; Dirección Sub-Regional de Salud Piura II, Ministerio de Salud, Sullana, Peru; Office of the Director, National Center for Infectious Diseases, Centers for Disease Control and Prevention, U.S. Naval Medical Research Center Detachment, Lima, Peru
Search for other papers by ANA MARIA PALACIOS in
Current site
Google Scholar
PubMed
Search for other papers by ANA MARIA PALACIOS in
Current site
Google Scholar
PubMed
EDUARDO FALCONÍ
EDUARDO FALCONÍ
Instituto Nacional de Salud, Lima, Peru; Dirección Sub-Regional de Salud Piura II, Ministerio de Salud, Sullana, Peru; Office of the Director, National Center for Infectious Diseases, Centers for Disease Control and Prevention, U.S. Naval Medical Research Center Detachment, Lima, Peru
Search for other papers by EDUARDO FALCONÍ in
Current site
Google Scholar
PubMed
Search for other papers by EDUARDO FALCONÍ in
Current site
Google Scholar
PubMed
CÉSAR CABEZAS
CÉSAR CABEZAS
Instituto Nacional de Salud, Lima, Peru; Dirección Sub-Regional de Salud Piura II, Ministerio de Salud, Sullana, Peru; Office of the Director, National Center for Infectious Diseases, Centers for Disease Control and Prevention, U.S. Naval Medical Research Center Detachment, Lima, Peru
Search for other papers by CÉSAR CABEZAS in
Current site
Google Scholar
PubMed
Search for other papers by CÉSAR CABEZAS in
Current site
Google Scholar
PubMed
NANCY ARRÓSPIDE
NANCY ARRÓSPIDE
Instituto Nacional de Salud, Lima, Peru; Dirección Sub-Regional de Salud Piura II, Ministerio de Salud, Sullana, Peru; Office of the Director, National Center for Infectious Diseases, Centers for Disease Control and Prevention, U.S. Naval Medical Research Center Detachment, Lima, Peru
Search for other papers by NANCY ARRÓSPIDE in
Current site
Google Scholar
PubMed
Search for other papers by NANCY ARRÓSPIDE in
Current site
Google Scholar
PubMed
SONIA GUTIERREZ
SONIA GUTIERREZ
Instituto Nacional de Salud, Lima, Peru; Dirección Sub-Regional de Salud Piura II, Ministerio de Salud, Sullana, Peru; Office of the Director, National Center for Infectious Diseases, Centers for Disease Control and Prevention, U.S. Naval Medical Research Center Detachment, Lima, Peru
Search for other papers by SONIA GUTIERREZ in
Current site
Google Scholar
PubMed
Search for other papers by SONIA GUTIERREZ in
Current site
Google Scholar
PubMed
TRENTON K. RUEBUSH II
TRENTON K. RUEBUSH II
Instituto Nacional de Salud, Lima, Peru; Dirección Sub-Regional de Salud Piura II, Ministerio de Salud, Sullana, Peru; Office of the Director, National Center for Infectious Diseases, Centers for Disease Control and Prevention, U.S. Naval Medical Research Center Detachment, Lima, Peru
Search for other papers by TRENTON K. RUEBUSH II in
Current site
Google Scholar
PubMed
Search for other papers by TRENTON K. RUEBUSH II in
Current site
Google Scholar
PubMed
To assist the Peruvian Ministry of Health in modifying the malaria treatment policy for their north Pacific coastal region, we conducted an in vivo efficacy trial of sulfadoxine-pyrimethamine (SP) and SP plus artesunate (SP-AS) for the treatment for uncomplicated Plasmodium falciparum infections. A total of 197 patients were randomized to therapy with either SP (25 mg/kg of the sulfadoxine component in a single dose on day 0) or a combination of SP plus AS (4 mg/kg on days 0, 1, and 2) and were followed for 28 days for symptoms and recurrence of parasitemia. No statistically significant differences between the two groups were observed on enrollment with respect to age, sex, history of malaria, or geometric mean parasite density. A total of 185 subjects completed the 28-day follow-up. Of the 91 subjects treated with SP alone, two had recurrences of parasitemia on day 7 and one on day 21. Of the 94 subjects treated with SP-AS, one had a recurrence of parasitemia on day 21. Fever and asexual parasite density decreased significantly more rapidly and the proportion of patients with gametocytemia on days 3–28 was significantly lower in subjects treated with combination therapy than in those who received SP alone. No severe adverse drug reactions were observed; however, self-limited rash and pruritis were significantly more common and an exacerbation of nausea, vomiting, and abdominal pain were observed significantly more frequently among patients who had received SP-AS. These results have contributed to a National Malaria Control Program decision to change to SP-AS combination therapy as the first-line treatment for uncomplicated P. falciparum malaria in northern coastal Peru in November 2001, making Peru the first country in the Americas to recommend this combination therapy.
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1
White NJ, 1998. Preventing antimalarial drug resistance through combinations. Drug Resist Updates 1 :3–9.
-
2
White NJ, Nosten F, Looareesuwan S, Watkins WM, Marsh K, Snow RW, Kokwara G, Ouma J, Hien TT, Molyneux ME, Taylor TE, Newbold CI, Ruebush TK II, Danis M, Greenwood BM, Anderson RM, Olliaro P, 1999. Averting a malaria disaster. Lancet 353 :1965–1967.
-
3
WHO, 1998. The Use of Artemisinin and Its Derivatives as Anti-Malarial Drugs: Report of a Joint CTD/DMP/TDR Informal Consultation. Geneva: World Health Organization. WHO Document WHO/MAL/98.1086
-
4
Nosten F, van Vugt M, Price R, Luxemburger C, Thway KL, Brockman A, McGready R, ter Kuile F, Looareesuwan S, White NJ, 2000. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet 356 :297–302.
-
5
White NJ, 1997. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother 41 :1413–1422.
-
6
Price RN, Nosten F, Luxemburger C, ter Kuile FO, Paiphun L, Chongsuphajaisiddhi T, White NJ, 1996. Effects of artemisinin derivatives on malaria transmissibility. Lancet 347 :1654–1658.
-
7
Doherty F, Sadiq AD, Bayo L, Alloueche A, Olliaro P, Milligan P, von Seidlein L, Pinder M, 1999. A randomized safety and tolerability trial of artresunate plus sulfadoxine-pyrimethamine versus sulfadoxine-pyrimethamine alone for the treatment of uncomplicated malaria in Gambian children. Trans R Soc Trop Med Hyg 93 :543–546.
-
8
von Seidlein L, Jawara M, Coleman R, Doherty T, Walraven G, Targett G, 2001. Parasitaemia and gametocytaemia after treatment with chloroquine, pyrimethamine/sulfadoxine, and pyrimethamine/sulfadoxine combined with artesunate in young Gambians with uncomplicated malaria. Trop Med Int Health 6 :92–98.
-
9
von Seidlein L, Milligan P, Pinder M, Bojang K, Anyalebechi C, Gosling R, Coleman R, Ude JI, Sadiq A, Duraisingh M, Warhurst D, Alloueche A, Targett A, McAdam K, Greenwood B, Walraven G, Olliaro P, Doherty T, 2000. Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in Gambian children: a double-blind, randomised, controlled trial. Lancet 355 :352–357.
-
10
Marquiño W, MacArthur JR, Barat LM, Oblitas FE, Arrunátegui M, Garavito G, Chafloque ML, Pardavé B, Gutierrez S, Arróspide N, Carrillo C, Cabezas C, Ruebush TK II, 2003. Efficacy of chloroquine, sulfadoxine-pyrimethamine, and mefloquine for the treatment of uncomplicated Plasmodium falciparum malaria on the north coast of Peru. Am J Trop Med Hyg 68 :120–123.
-
11
Ministerio de Salud, Peru, 1999. Política Nacional de Medicamentos para el Control de la Malaria en el Perú. Lima: MINSA.
-
12
Bruce-Chwatt LJ, Black RH, Canfield CJ, Clyde DR, Peters W, 1986. Chemotherapy of Malaria. World Health Organization Monograph Series No. 27, Geneva: World Health Organization.
-
13
Pan American Health Organization, 1998. Evaluation of the Therapeutic Efficacy of Drugs for the Treatment of Uncomplicated Plasmodium falciparum Malaria in the Americas. Washington, DC: Pan American Health Organization. OPS/HCP/HCT/113/98.
-
14
Ministry of Public Health, Thailand, 1996. Post-Registration Surveillance of the Artemisinin Derivatives Used Operationally in Thailand. Nonthaburi, Thailand: Technical Division, Food and Drug Administration.
-
15
Ribiero IR, Olliaro P, 1998. Safety of artemisinin and its derivatives: a review of published and unpublished clinical trials. Med Trop (Mars) 58 :50–53.
-
16
Botero D, Restrepo M, Montoya A, 1985. Prospective double-blind trial of two different doses of mefloquine plus pyrimethamine-sulfadoxine compared with pyrimethamine-sulfadoxine alone in the treatment of falciparum malaria. Bull World Health Organ 3 :731–737.
-
17
Reyes S, Osanai CH, Costa Passos AD, 1986. Resistência in vivo do Plasmodium falciparum as 4-aminoquinoleínas e á associação sulfadoxina-pirimetamina. II. Estudio de Manaus, Amazonas 1983–1984. Rev Bras Mal Doencas Trop 38 :37–44.
-
18
Osorio LE, Giraldo LE, Grajales LF, Arriaga AL, Andrade AL, Ruebush TK, Barat LM, 1999. Assessment of the therapeutic response of Plasmodium falciparum to chloroquine and sulfadoxine-pyrimethamine in an area of low malaria transmission in Colombia. Am J Trop Med Hyg 61 :968–972.
-
19
Nwanyanwu OC, Ziba C, Macheso A, Kazembe P, 2000. Efficacy of sulphadoxine-pyrimethamine for acute uncomplicated malaria due to Plasmodium falciparum in Malawian children under five years old. Trop Med Int Health 5 :355–358.
-
20
White NJ, 1992. Antimalarial drug resistance: the pace quickens. J Antimicrob Agents Chemother 30 :571–585.
-
21
Watkins WM, Mosobo M, 1993. Treatment of Plasmodium falciparum malaria with PSD: selective pressure for resistance is a function of long elimination half life. Trans R Soc Trop Med Hyg 87 :75–78.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 59 | 59 | 8 |
| Full Text Views | 239 | 73 | 0 |
| PDF Downloads | 44 | 14 | 0 |